Study details
Enrolling now
Danvatirsen and Venetoclax in Relapsed/Refractory MDS & AML
Montefiore Medical Center
NCT IDNCT05986240ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
38
Study length
about 5.9 years
Ages
18+
Locations
2 sites in NY, TX
About this study
Researchers are testing the safety and effectiveness of Danvatirsen alone, followed by Danvatirsen combined with Venetoclax, in people whose leukemia (MDS or AML) has returned after treatment or hasn't responded to previous treatments. The trial will last for about 2 years.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Danvatirsen
- 2.Take Danvatirsen + Venetoclax
PhasePhase 1
DrugVenetoclax
Routeoral
Primary goalResponse to Therapy as determined by Overall Response Rate
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
venetoclax
Drug routes
oral
Endpoints
Primary: Response to Therapy as determined by Overall Response Rate
Secondary: Duration of Response, Event-free survival, Overall Survival
Body systems
Oncology